keyword
https://read.qxmd.com/read/38630129/monocyte-to-platelets-ratio-mpr-at-diagnosis-is-associated-with-inferior-progression-free-survival-in-patients-with-mantle-cell-lymphoma-a-multi-center-real-life-survey
#21
JOURNAL ARTICLE
Andrea Duminuco, Alessandra Romano, Isacco Ferrarini, Gabriella Santuccio, Annalisa Chiarenza, Amalia Figuera, Laura Anastasia Caruso, Giovanna Motta, Giuseppe Alberto Palumbo, Carlo Mogno, Alessia Moioli, Francesco Di Raimondo, Carlo Visco
Mantle cell lymphoma (MCL) pathogenesis is strongly related to the role of the tumor immune microenvironment (TIME) in which MCL cells proliferate. TIME cells can produce growth signals influencing MCL cells' survival and exert an antitumoral immune response suppression. The activity of TIME cells might be mirrored by some ratios of peripheral blood cell subpopulations, such as the monocyte-to-platelet ratio (MPR). We reviewed the clinical features of 165 consecutive MCL patients newly diagnosed and not eligible for autologous stem cell transplantation (both for age or comorbidities) who accessed two Italian Centers between 2006 and 2020...
April 17, 2024: Annals of Hematology
https://read.qxmd.com/read/38627868/altered-skin-microbiome-inflammation-and-jak-stat-signaling-in-southeast-asian-ichthyosis-patients
#22
JOURNAL ARTICLE
Minh Ho, Huynh-Nga Nguyen, Minh Van Hoang, Tien Thuy Thi Bui, Bao-Quoc Vu, Truc Huong Thi Dinh, Hoa Thi My Vo, Diana C Blaydon, Sherif A Eldirany, Christopher G Bunick, Chi-Bao Bui
BACKGROUND: Congenital ichthyosis (CI) is a collective group of rare hereditary skin disorders. Patients present with epidermal scaling, fissuring, chronic inflammation, and increased susceptibility to infections. Recently, there is increased interest in the skin microbiome; therefore, we hypothesized that CI patients likely exhibit an abnormal profile of epidermal microbes because of their various underlying skin barrier defects. Among recruited individuals of Southeast Asian ethnicity, we performed skin meta-genomics (i...
April 16, 2024: Human Genomics
https://read.qxmd.com/read/38626745/prognostic-implications-of-circulating-plasma-cell-percentage-in-multiple-myeloma-and-primary-plasma-cell-leukemia-defined-by-new-criteria
#23
JOURNAL ARTICLE
Xianghong Jin, Xianyong Jiang, Hui Li, Kaini Shen, Shuangjiao Liu, Miao Chen, Chen Yang, Bing Han, Junling Zhuang
INTRODUCTION: The definition of primary plasma cell leukemia (pPCL) has been revised from ≥20% to ≥5% circulating plasma cells (CPC). However, the precise prognosis associated with CPC remains controversial. This study aimed to investigate prognostic biomarkers for myeloma patients based on CPC presence. METHODS: A comprehensive analysis was conducted on 309 consecutive patients diagnosed with either multiple myeloma or pPCL, utilizing peripheral blood smears stained with Wright-Giemsa...
April 16, 2024: Acta Haematologica
https://read.qxmd.com/read/38625068/neutrophil-generation-from-hematopoietic-progenitor-cells-and-induced-pluripotent-stem-cells-ipscs-potential-applications
#24
REVIEW
Abdollah Jafarzadeh, Marzieh Motaghi, Sanand Kumar Patra, Zahra Jafarzadeh, Maryam Nemati, Bhaskar Saha
Neutrophils are the most frequent immune cell type in peripheral blood, performing an essential role against pathogens. People with neutrophil deficiencies are susceptible to deadly infections, highlighting the importance of generating these cells in host immunity. Neutrophils can be generated from hematopoietic progenitor cells (HPCs) and embryonic stem cells (ESCs) using a cocktail of cytokines. In addition, induced pluripotent stem cells (iPSCs) can be differentiated into various functional cell types, including neutrophils...
March 30, 2024: Cytotherapy
https://read.qxmd.com/read/38623681/a-case-of-blastic-plasmacytoid-dendritic-cell-neoplasm-with-orbital-tumor-as-the-initial-symptom
#25
Peizhang Li, Naiqi Pang, Meiqin Li, Juan Xie, Ying Wang
BACKGROUND: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy arising from precursor dendritic cells. It is a rare and challenging clinical presentation. For decades, there has been no treatment course for managing BPDCN and its overall prognosis is poor. METHODS AND RESULTS: We report a 27-year-old man who was admitted to the hospital due to an orbital tumor as the first symptom. Progressive enlargement of the orbital tumor was accompanied by multiple purple circular nodules on the body trunk...
April 1, 2024: Clinical Laboratory
https://read.qxmd.com/read/38621748/tumor-organoids-the-era-of-personalized-medicine
#26
REVIEW
Natalia V Rassomakhina, Alexandra Yu Ryazanova, Astemir R Likhov, Sergey A Bruskin, Liliya G Maloshenok, Victoria V Zherdeva
The strategies of future medicine are aimed to modernize and integrate quality approaches including early molecular-genetic profiling, identification of new therapeutic targets and adapting design for clinical trials, personalized drug screening (PDS) to help predict and individualize patient treatment regimens. In the past decade, organoid models have emerged as an innovative in vitro platform with the potential to realize the concept of patient-centered medicine. Organoids are spatially restricted three-dimensional clusters of cells ex vivo that self-organize into complex functional structures through genetically programmed determination, which is crucial for reconstructing the architecture of the primary tissue and organs...
January 2024: Biochemistry. Biokhimii︠a︡
https://read.qxmd.com/read/38616351/post-transplant-cyclophosphamide-and-short-term-everolimus-as-graft-versus-host-prophylaxis-in-patients-with-relapsed-refractory-lymphoma-and-myeloma-final-results-of-the-phase-ii-octet-ever-trial
#27
JOURNAL ARTICLE
Tim Richardson, Christof Scheid, Marco Herling, Lukas P Frenzel, Carmen Herling, Marta Rebecca Cruz Aguilar, Sebastian Theurich, Michael Hallek, Udo Holtick
BACKGROUND: Conditioning regimens and the choice of immunosuppression have substantial impact on immune reconstitution after allogeneic hematopoietic stem cell transplantation (aHSCT). The pivotal mechanism to maintain remission is the induction of the graft-versus-tumor effect. Relapse as well as graft versus host disease remain common. Classic immunosuppressive strategies implementing calcineurin inhibitors (CNI) have significant toxicities, hamper the immune recovery, and reduce the anti-cancer immune response...
April 14, 2024: European Journal of Haematology
https://read.qxmd.com/read/38616211/what-is-new-in-acute-myeloid-leukemia-classification
#28
REVIEW
Hee Sue Park
Recently, the International Consensus Classification (ICC) and the 5th edition of the World Health Organization classification (WHO2022) introduced diagnostically similar yet distinct approaches, which has resulted in practical confusion. This review compares these classification systems for acute myeloid leukemia (AML), building up on the revised 4th edition of WHO (WHO2016). Both classifications retain recurrent genetic abnormalities as a primary consideration. However, they differ in terms of blast threshold...
April 15, 2024: Blood Research
https://read.qxmd.com/read/38615378/combination-of-chidamide-and-pd-1-blockade-in-refractory-relapsed-aggressive-large-b-cell-lymphomas-with-high-risk-of-failing-car-t-therapy
#29
JOURNAL ARTICLE
Zhenhao Wang, Hao Xu, Yu Mei, Min Xiao, Yang Cao, Liang Huang, Zhuming Yang, Yicheng Zhang, Zhiqiang Han, Miao Zheng, Zhenya Hong
BACKGROUND: Refractoriness and relapse after chimeric antigen receptor T-cell therapy have emerged as major challenges for immunotherapy of aggressive large B-cell lymphoma. Thus far, there is no consensus on how to address treatment failure and whether to administer maintenance therapy following CAR-T cell therapy. METHODS: From August 2017 through November 2022, 52 patients with refractory/relapsed aggressive LBCL who had a high risk of resistance to CAR-T cell therapy were given chidamide in combination with a PD-1 inhibitor as maintenance therapy following either CAR19/22 T-cell cocktail therapy or CAR19/22 T-cell cocktail therapy plus autologous stem cell transplantation (ASCT)...
April 13, 2024: International Immunopharmacology
https://read.qxmd.com/read/38610025/ganoderma-spore-lipid-ameliorates-docetaxel-cisplatin-and-5-fluorouracil-chemotherapy-induced-damage-to-bone-marrow-mesenchymal-stem-cells-and-hematopoiesis
#30
JOURNAL ARTICLE
Haohui Lin, Manhon Chung, Jingchun Sun, Yi Yang, Li Zhang, Xiaohua Pan, Minghui Wei, Sa Cai, Yu Pan
BACKGROUND: A triplet chemotherapy regimen of docetaxel, cisplatin, and 5-fluorouracil (TPF) is used to treat head and neck squamous cell carcinoma; however, it is toxic to bone marrow mesenchymal stem cells (BMSCs). We previously demonstrated that Ganoderma spore lipid (GSL) protect BMSCs against cyclophosphamide toxicity. In this study, we investigated the protective effects of GSL against TPF-induced BMSCs and hematopoietic damage. METHODS: BMSCs and C57BL/6 mice were divided into control, TPF, co-treatment (simultaneously treated with GSL and TPF for 2 days), and pre-treatment (treated with GSL for 7 days before 2 days of TPF treatment) groups...
April 12, 2024: BMC complementary medicine and therapies
https://read.qxmd.com/read/38609316/phase-1-study-combining-elotuzumab-with-autologous-stem-cell-transplant-and-lenalidomide-for-multiple-myeloma
#31
JOURNAL ARTICLE
David G Coffey, Keren Osman, Adolfo Aleman, Selma Bekri, Simone Kats, Amishi Dhadwal, Donna Catamero, Seunghee Kim-Schulze, Sacha Gnjatic, Ajai Chari, Samir Parekh, Sundar Jagannath, Hearn Jay Cho
BACKGROUND: Autologous stem cell transplantation (ASCT) after induction therapy improves disease-free survival for patients with multiple myeloma (MM). While the goal of ASCT is to render a minimal disease state, it is also associated with eradication of immunosuppressive cells, and we hypothesize that early introduction of immunotherapy post-ASCT may provide a window of opportunity to boost treatment efficacy. METHODS: We conducted a phase 1 clinical trial to investigate the application of autologous lymphocyte infusion and anti-SLAMF7 monoclonal antibody, elotuzumab, after ASCT in patients with newly diagnosed MM previously treated with induction therapy...
April 12, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38608356/generation-and-characterization-of-the-ips-cell-line-sysushi001-a-derived-from-the-peripheral-blood-mononuclear-cells-pbmcs-of-a-33-year-old-patient-with-acute-myeloid-leukemia-aml
#32
JOURNAL ARTICLE
Lihua Yuan, Mei Xie, Yuan Tao, Xi Chen, Xiaojun Xu, Xiaobo Wang
We successfully developed an induced pluripotent stem cell (iPSC) line, SYSUSHi001-A, from the peripheral blood mononuclear cells (PBMC) of a patient with Acute Myeloid Leukemia, harboring two genetic mutations (XPO1: c.591-4_591-3dupTT; PALB2: c.3296C > T; p.T1099M). This iPSC line was facilitated through the use of episomal plasmids encoding OCT4, SOX2, KLF4, L-MYC, and human miR-302. The SYSUSHi001-A iPSC line exhibited characteristic embryonic stem cell-like morphology, maintained the XPO1 and PALB2 mutations, expressed key pluripotency markers, preserved a normal karyotype (46, XY), and demonstrated the ability to differentiate into cells from all three germ layers in vitro...
February 23, 2024: Stem Cell Research
https://read.qxmd.com/read/38607553/loss-of-nlrp6-expression-increases-the-severity-of-intestinal-injury-after-syngeneic-hematopoietic-stem%C3%A2-cell-transplantation
#33
JOURNAL ARTICLE
Shengyun Zhu, Xue Zhang, Kairen Xu, Jing Liang, Weiwei Wang, Lingyu Zeng, Kailin Xu
NLRP6 plays a crucial role in maintaining intestinal homeostasis by regulating the interaction between the intestinal mucosa and the microbiota. However, the impact of NLRP6 deficiency on intestinal damage following hematopoietic stem cell transplantation (HSCT) remains poorly understood. In this study, we established a syngeneic HSCT mouse model using C57BL/6 mice as donors and NLRP6-/- or C57BL/6 mice as recipients. Our findings revealed that NLRP6 deficiency had minimal influence on peripheral blood cell counts and splenic immune cell proportions in transplanted mice...
April 12, 2024: Annals of Hematology
https://read.qxmd.com/read/38607317/activated-and-na%C3%A3-ve-allogenic-human-placental-mesenchymal-stromal-cells-exert-an-immunomodulatory-effect-on-hidradenitis-suppurativa-patient-peripheral-blood-mononuclear-cells
#34
JOURNAL ARTICLE
Vaiva Jariene, Paulius Valiukevicius, Justinas Maciulaitis, Ugne Kuzaityte, Ruta Insodaite, Ieva Ciapiene, Romaldas Maciulaitis, Skaidra Valiukeviciene
This pilot study aimed to evaluate the immunomodulatory effect of placental mesenchymal stem/stromal cells (MSCs) on peripheral blood mononuclear cells (PBMCs) from patients with hidradenitis suppurativa (HS). Blood samples were collected from 3 healthy and 3 patients with HS. Isolated PBMCs were stained with carboxyfluorescein succinimidyl ester (CFSE) and stimulated with phorbol 12-myristate 13-acetate (PMA)/Ionomycin solution. The PBMCs of patients with HS were co-cultured with naïve MSCs (n-MSCs), activated with tumor necrosis factor (TNF)-α (10 ng/mL) and interferon (IFN)-γ (10 ng/mL) MSCs (a-MSCs), or adalimumab (30 μg/mL)...
April 12, 2024: Journal of Interferon & Cytokine Research
https://read.qxmd.com/read/38604790/-haploidentical-donor-peripheral-blood-stem-cell-transplantation-using-third-party-cord-blood-compared-with-matched-unrelated-donor-transplantation-for-patients-with-hematologic-malignancies
#35
JOURNAL ARTICLE
X Ma, Y Chen, Y Liu, T T Cheng, X Chen, C Zeng, J Hua, S Y Wang, Y J Xu
Objectives: To assess the efficacy of cord blood-assisted haploid peripheral blood stem cell transplantation (haplo-cord-PBSCT) versus unrelated donor peripheral blood stem cell transplantation (UD-PBSCT) in the treatment of malignant hematological diseases. Methods: A retrospective analysis was performed on one hundred and four patients with malignant hematological diseases who underwent haplo-cord-PBSCT and fifty-two patients who underwent UD-PBSCT at Xiangya Hospital of Central South University between January 2016 and December 2021...
February 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38604785/-expert-consensus-on-clonal-screening-and-monitoring-of-complement-inhibitor-therapy-in-paroxysmal-nocturnal-hemoglobinuria-2024
#36
JOURNAL ARTICLE
(no author information available yet)
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal disease with abnormal hematopoietic stem cells that causes intravascular hemolytic anemia, thrombosis, and peripheral blood cytopenia. It has a chronic progressive course and can be fatal in severe cases if not treated aggressively. Complement inhibitors are the first-line recommended treatment for hemolysis-related symptoms of PNH. With the rapid development of new complement inhibitors, it is critical to quickly screen and confirm the diagnosis, identify patients with complement inhibitor indications, and monitor breakthrough hemolysis and extravascular hemolysis during complement inhibitor therapy...
February 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38594416/comparable-outcomes-of-allogeneic-peripheral-blood-versus-bone-marrow-hematopoietic-stem-cell-transplantation-from-a-sibling-donor-for-pediatric-patients
#37
JOURNAL ARTICLE
Bo Kyung Kim, Kyung Taek Hong, Jung Yoon Choi, Hyery Kim, Hyun Jin Park, Hyoung Jin Kang
Traditionally, bone marrow (BM) has been preferred as a source of stem cells (SCs) in pediatric hematopoietic SC transplantation (HSCT); however, the use of peripheral blood SCs (PBSC) has recently increased. With advancing graft-versus-host disease (GVHD) prophylaxis, whether the BM is still a better SC source than PB in sibling donor HSCT remains controversial. Here, we compared the results of BM transplantation (BMT) and PBSC transplantation (PBSCT) in pediatric patients with malignant or non-malignant diseases receiving sibling HSCT using a total of 7...
April 10, 2024: Annals of Hematology
https://read.qxmd.com/read/38593812/myeloid-t-cell-interplay-and-cell-state-transitions-associated-with-checkpoint-inhibitor-response-in-melanoma
#38
JOURNAL ARTICLE
Ramona Schlenker, Petra C Schwalie, Steffen Dettling, Tamara Huesser, Anja Irmisch, Marisa Mariani, Julia M Martínez Gómez, Alison Ribeiro, Florian Limani, Sylvia Herter, Emilio Yángüez, Sabine Hoves, Jitka Somandin, Juliane Siebourg-Polster, Tony Kam-Thong, Ines Grazina de Matos, Pablo Umana, Reinhard Dummer, Mitchell P Levesque, Marina Bacac
BACKGROUND: The treatment of melanoma, the deadliest form of skin cancer, has greatly benefited from immunotherapy. However, many patients do not show a durable response, which is only partially explained by known resistance mechanisms. METHODS: We performed single-cell RNA sequencing of tumor immune infiltrates and matched peripheral blood mononuclear cells of 22 checkpoint inhibitor (CPI)-naive stage III-IV metastatic melanoma patients. After sample collection, the same patients received CPI treatment, and their response was assessed...
April 4, 2024: Med
https://read.qxmd.com/read/38591343/against-all-odds-the-road-to-success-in-the-development-of-human-immune-reconstitution-mice
#39
REVIEW
Yixiao Bin, Jing Ren, Haowei Zhang, Tianjiao Zhang, Peijuan Liu, Zhiqian Xin, Haijiao Yang, Zhuan Feng, Zhinan Chen, Hai Zhang
The mouse genome has a high degree of homology with the human genome, and its physiological, biochemical, and developmental regulation mechanisms are similar to those of humans; therefore, mice are widely used as experimental animals. However, it is undeniable that interspecies differences between humans and mice can lead to experimental errors. The differences in the immune system have become an important factor limiting current immunological research. The application of immunodeficient mice provides a possible solution to these problems...
April 9, 2024: Animal Models and Experimental Medicine
https://read.qxmd.com/read/38581299/effects-of-cd34-cell-dose-on-engraftment-and-long-term-outcomes-after-allogeneic-bone-marrow-transplantation
#40
JOURNAL ARTICLE
Takashi Oyama, Shin-Ichiro Fujiwara, Ryutaro Tominaga, Daizo Yokoyama, Atsuto Noguchi, Shuka Furuki, Shunsuke Koyama, Rui Murahashi, Hirotomo Nakashima, Kazuki Hyodo, Takashi Ikeda, Shin-Ichiro Kawaguchi, Yumiko Toda, Takashi Nagayama, Kento Umino, Daisuke Minakata, Kaoru Morita, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Ikuko Otsuki, Ken Ohmine, Yoshinobu Kanda
BACKGROUND: The number of CD34+ cells in the graft is generally associated with time to engraftment and survival in transplantation using cord blood or allogeneic peripheral blood stem cells. However, the significance of abundant CD34+ in bone marrow transplantation (BMT) remained unclear. METHODS: We retrospectively reviewed 207 consecutive adult patients who underwent their first BMT at Jichi Medical University between January 2009 and June 2021. RESULTS: The median nucleated cell count (NCC) and CD34+ cell dose were 2...
April 2024: Clinical Transplantation
keyword
keyword
83569
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.